[Vaccinations in recurrent urinary tract infections--an observation study relating to health economy]

Aktuelle Urol. 2009 Nov;40(6):360-5. doi: 10.1055/s-0029-1124677. Epub 2009 Nov 6.
[Article in German]

Abstract

Background and purpose: Urinary tract infection (UTI) is one of the most common bacterial infections in women. Despite the need for therapy alter-natives only the conventional treatment using antibiotics is investigated in the literature. A vaccination, however, can be a useful medical and economic alternative for the treatment of recurrent urinary tract infections.

Materials and methods: An open, prospective, not-randomised, multicentric observation study was carried out to determine the costs and effects of a vaccination in 842 patients with recurrent urinary tract infections. The data for efficacy, safety and costs of recurrent urinary tract infections were collected via patient documentation and a standardised documentation of the physicians.

Results: The efficacy was rated as good to very good by 82.7 % of the physicians and 82.1 % of the patients. The values for safety show even better results. They were rated as good to very good by 92.4 % of the physicians and 90.9 % of the patients. The total costs amounted to 433 euro per patient in the six months before vaccination and decreased significantly to 238 euro in the six months after vaccination (p < 0.0001).

Conclusions: The results of this observation study show a clinically relevant reduction of recurrent urinary tract infections with acceptable side effects in the six months after vaccination. As the treatment costs are reduced from a mean of 238 euro to 91 euro per patient. The healthcare insurances can also benefit from the vaccination against recurrent urinary tract infections.

Publication types

  • English Abstract
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bacterial Vaccines / administration & dosage*
  • Bacterial Vaccines / economics*
  • Cost-Benefit Analysis / statistics & numerical data
  • Female
  • Follow-Up Studies
  • Germany
  • Health Care Costs / statistics & numerical data*
  • Humans
  • Immunization, Secondary / economics
  • Male
  • Middle Aged
  • National Health Programs / economics*
  • Prospective Studies
  • Recurrence
  • Treatment Outcome
  • Urinary Tract Infections / economics*
  • Urinary Tract Infections / microbiology
  • Urinary Tract Infections / prevention & control*
  • Vaccination / economics*
  • Vaccines, Inactivated / administration & dosage*
  • Vaccines, Inactivated / economics*
  • Young Adult

Substances

  • Bacterial Vaccines
  • Vaccines, Inactivated